20.5  12.34 (151.23%)		10-10 16:00
Open: 12.21 High: 41.8 Volume: 13,502,074		Pre. Close: 8.16 Low: 11.71 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	33.19	1-year :	48.82
Resists	First :	28.41	Second :	41.79
Pivot price	8.26
Supports	First :	6.77	Second :	5.63
MAs	MA(5) :	10.41	MA(20) :	8.21
	MA(100) :	8.18	MA(250) :	12.66
MACD	MACD :	1	Signal :	0.1
%K %D	K(14,3) :	70	D(3) :	60.9
RSI	RSI(14): 92.9
52-week	High :	54.95	Low :	5.01

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ QNRX ] has closed above the upper band by 43.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 627% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	41.85 - 42.01	42.01 - 42.16
Low:	11.58 - 11.64	11.64 - 11.69
Close:	20.33 - 20.49	20.49 - 20.63

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Fri, 10 Oct 2025
Crude Oil Falls Over 4%; Quoin Pharmaceuticals Shares Spike Higher - Benzinga

Fri, 10 Oct 2025
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga

Fri, 10 Oct 2025
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com

Fri, 10 Oct 2025
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million - GlobeNewswire

Fri, 10 Oct 2025
Up to $104.5M: Quoin Pharmaceuticals Secures Private Placement with 7.98M ADS Warrants - Stock Titan

Tue, 09 Sep 2025
Twin Sisters Share Life-Changing Impact of Rare Netherton Syndrome in Quoin Pharma's Documentary Series - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	4 (M)
Held by Insiders	0.2 (%)
Held by Institutions	0.1 (%)
Shares Short	4 (K)
Shares Short P.Month	6 (K)

EPS	958.65
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-69.1 %
Return on Equity (ttm)	-242.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-21.39
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	0.02
PEG Ratio	0
Price to Book value	4.72
Price to Sales	0
Price to Cash Flow	-1.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.